These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
789 related articles for article (PubMed ID: 19221875)
1. A novel doxorubicin-mitomycin C co-encapsulated nanoparticle formulation exhibits anti-cancer synergy in multidrug resistant human breast cancer cells. Shuhendler AJ; Cheung RY; Manias J; Connor A; Rauth AM; Wu XY Breast Cancer Res Treat; 2010 Jan; 119(2):255-69. PubMed ID: 19221875 [TBL] [Abstract][Full Text] [Related]
2. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer. Wong HL; Bendayan R; Rauth AM; Wu XY J Control Release; 2006 Dec; 116(3):275-84. PubMed ID: 17097178 [TBL] [Abstract][Full Text] [Related]
3. A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system. Wong HL; Bendayan R; Rauth AM; Xue HY; Babakhanian K; Wu XY J Pharmacol Exp Ther; 2006 Jun; 317(3):1372-81. PubMed ID: 16547167 [TBL] [Abstract][Full Text] [Related]
4. In vivo evaluation of a new polymer-lipid hybrid nanoparticle (PLN) formulation of doxorubicin in a murine solid tumor model. Wong HL; Rauth AM; Bendayan R; Wu XY Eur J Pharm Biopharm; 2007 Mar; 65(3):300-8. PubMed ID: 17156986 [TBL] [Abstract][Full Text] [Related]
5. Synergistic nanoparticulate drug combination overcomes multidrug resistance, increases efficacy, and reduces cardiotoxicity in a nonimmunocompromised breast tumor model. Shuhendler AJ; Prasad P; Zhang RX; Amini MA; Sun M; Liu PP; Bristow RG; Rauth AM; Wu XY Mol Pharm; 2014 Aug; 11(8):2659-74. PubMed ID: 24830351 [TBL] [Abstract][Full Text] [Related]
6. Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models. Peer D; Dekel Y; Melikhov D; Margalit R Cancer Res; 2004 Oct; 64(20):7562-9. PubMed ID: 15492283 [TBL] [Abstract][Full Text] [Related]
7. Effects of mitomycin C and carboplatin pretreatment on multidrug resistance-associated P-glycoprotein expression and on subsequent suppression of tumor growth by doxorubicin and paclitaxel in human metastatic breast cancer xenografted nude mice. Ihnat MA; Nervi AM; Anthony SP; Kaltreider RC; Warren AJ; Pesce CA; Davis SA; Lariviere JP; Hamilton JW Oncol Res; 1999; 11(7):303-10. PubMed ID: 10757444 [TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo characterization of a combination chemotherapy formulation consisting of vinorelbine and phosphatidylserine. Webb MS; Johnstone S; Morris TJ; Kennedy A; Gallagher R; Harasym N; Harasym T; Shew CR; Tardi P; Dragowska WH; Mayer LD; Bally MB Eur J Pharm Biopharm; 2007 Mar; 65(3):289-99. PubMed ID: 17123800 [TBL] [Abstract][Full Text] [Related]
9. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel. Chang CC; Liang YC; Klutz A; Hsu CI; Lin CF; Mold DE; Chou TC; Lee YC; Huang RC Cancer Chemother Pharmacol; 2006 Nov; 58(5):640-53. PubMed ID: 16544145 [TBL] [Abstract][Full Text] [Related]
10. Reversal effect of isotetrandrine, an isoquinoline alkaloid extracted from Caulis Mahoniae, on P-glycoprotein-mediated doxorubicin-resistance in human breast cancer (MCF-7/DOX) cells. Wang TX; Yang XH Yao Xue Xue Bao; 2008 May; 43(5):461-6. PubMed ID: 18717331 [TBL] [Abstract][Full Text] [Related]
11. REIC/Dkk-3 overexpression downregulates P-glycoprotein in multidrug-resistant MCF7/ADR cells and induces apoptosis in breast cancer. Kawasaki K; Watanabe M; Sakaguchi M; Ogasawara Y; Ochiai K; Nasu Y; Doihara H; Kashiwakura Y; Huh NH; Kumon H; Date H Cancer Gene Ther; 2009 Jan; 16(1):65-72. PubMed ID: 18654608 [TBL] [Abstract][Full Text] [Related]
12. Quercetin and doxorubicin co-encapsulated biotin receptor-targeting nanoparticles for minimizing drug resistance in breast cancer. Lv L; Liu C; Chen C; Yu X; Chen G; Shi Y; Qin F; Ou J; Qiu K; Li G Oncotarget; 2016 May; 7(22):32184-99. PubMed ID: 27058756 [TBL] [Abstract][Full Text] [Related]
13. [The in vitro cytotoxicity and in vivo toxicity of doxorubicin antiresistant stealth liposomes]. Wang JC; Liu XY; Lü WL; Lee HS; Goh BC; Zhang Q Yao Xue Xue Bao; 2005 May; 40(5):475-80. PubMed ID: 16220797 [TBL] [Abstract][Full Text] [Related]
14. Drug resistance in chemotherapy for breast cancer. Saeki T; Tsuruo T; Sato W; Nishikawsa K Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():84-9. PubMed ID: 16273361 [TBL] [Abstract][Full Text] [Related]
15. Linalool, a plant-derived monoterpene alcohol, reverses doxorubicin resistance in human breast adenocarcinoma cells. Ravizza R; Gariboldi MB; Molteni R; Monti E Oncol Rep; 2008 Sep; 20(3):625-30. PubMed ID: 18695915 [TBL] [Abstract][Full Text] [Related]
16. Reversal of P-glycoprotein-mediated multidrug resistance by guggulsterone in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells. Xu HB; Li L; Liu GQ Pharmazie; 2009 Oct; 64(10):660-5. PubMed ID: 19947169 [TBL] [Abstract][Full Text] [Related]
17. Doxorubicin and mitomycin C co-loaded polymer-lipid hybrid nanoparticles inhibit growth of sensitive and multidrug resistant human mammary tumor xenografts. Prasad P; Shuhendler A; Cai P; Rauth AM; Wu XY Cancer Lett; 2013 Jul; 334(2):263-73. PubMed ID: 22902994 [TBL] [Abstract][Full Text] [Related]
18. In vitro toxicity to breast cancer cells of microsphere-delivered mitomycin C and its combination with doxorubicin. Cheung RY; Rauth AM; Ronaldson PT; Bendayan R; Wu XY Eur J Pharm Biopharm; 2006 Apr; 62(3):321-31. PubMed ID: 16330194 [TBL] [Abstract][Full Text] [Related]
19. Synergistic anti-cancer effects of silibinin with conventional cytotoxic agents doxorubicin, cisplatin and carboplatin against human breast carcinoma MCF-7 and MDA-MB468 cells. Tyagi AK; Agarwal C; Chan DC; Agarwal R Oncol Rep; 2004 Feb; 11(2):493-9. PubMed ID: 14719089 [TBL] [Abstract][Full Text] [Related]
20. Reversion of multidrug resistance by co-encapsulation of doxorubicin and curcumin in chitosan/poly(butyl cyanoacrylate) nanoparticles. Duan J; Mansour HM; Zhang Y; Deng X; Chen Y; Wang J; Pan Y; Zhao J Int J Pharm; 2012 Apr; 426(1-2):193-201. PubMed ID: 22274587 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]